Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,1750€
Last updated
19/05/2026 - 14:55
-0,91%
€7.6m
Total sales in 2024
+40
Commercial opportunities following CellTolerance launch
+48%
PPU growth in 2024 vs.
2022
excluding exchange rates
Events and Presentations
Financial Results
Governance
AGM 2026 – Resolutions
No results found.
AGM 2026 – Candidate Profiles
No results found.
AGM 2026 – Notice of Meeting for Registered Shareholders
No results found.
AGM 2026 – Board’s Report on Resolutions
No results found.
2025 Annual Financial Report (free translation)
No results found.
News
Mauna Kea Technologies Announces Nomination of 3 New Directors
Publication of the 2025 Annual Financial Report
Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026
No results found.
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 79,439,997
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
ALLINVEST SECURITIES
Thibaut Voglimacci – Stephanopoli
EUROLAND CORPORATE
EUROLAND CORPORATE
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France